Method of assaying 5-fu
AssigneeMyriad Genetics, Inc.
InventorsBenjamin Roa, Carrie Colvin, Michael Overfield, Howard McLeod, Salvatore Salamone
Life of this patent
Estimating the term…
Abstract
The present invention provides methods, compositions, devices and kits for assaying 5-FU.
Claims9
A method of assaying 5-fluorouracil in a sample from a patient administered 5-FU or a prodrug thereof, said method comprising:
- measuring 5-fluorouracil in a sample obtained from said patient administered 5-fluorouracil or a prodrug thereof, wherein said sample is admixed in vitro with an inactivator of dihydropyrimide dehydrogenase after being obtained from said patient.
A method of treating a patient with 5-fluorouracil or a prodrug thereof, comprising:
- administering to said patient a first dose of 5-fluorouracil of a prodrug thereof;
- determining the amount of 5-fluorouracil in a sample obtained from said patient administered with 5-fluorouracil or said prodrug, wherein said sample is admixed in vitro with an inactivator of dihydropyrimide dehydrogenase;
- and
- administering to said patient a second dose of 5-fluorouracil or said prodrug after said determining step.
A method of processing a blood sample from a patient treated with a regimen comprising 5-fluorouracil or a prodrug thereof, for a 5-fluorouracil assay, said method comprising:
- obtaining a blood sample containing 5-fluorouracil from said patient;
- processing said blood sample by:
- (1) isolating plasma from said blood sample, and admixing the separated plasma with a first inactivator of dihydropyrimide dehydrogenase to form a first mixture;
- (2) admixing the blood sample with a second inactivator of dihydropyrimide dehydrogenase, and isolating therefrom plasma containing 5-fluorouracil and said inactivator forming a second mixture;
- or
- (3) admixing the blood sample with a third inactivator of dihydropyrimide dehydrogenase to form a third mixture;
- and
- sending said first, second or third mixture to a laboratory for said assay for 5-fluorouracil.
A composition comprising:
- a sample isolated from a patient treated with 5-fluorouracil, in admixture with
- an inactivator of dihydropyrimide dehydrogenase, wherein said inactivator is admixed in vitro with said sample.
A composition comprising an antibody selectively immunoreactive with 5-FU in admixture with a DPD inactivator.
A kit comprising in a container:
- a patient sample containing 5-fluorouracil isolated from a patient administered 5-fluorouracil or a prodrug thereof, in admixture with an inactivator of dihydropyrimide dehydrogenase, wherein said inactivator is admixed with said patient sample in vitro;
- and
- means for cooling said sample to a temperature below 10° C.
A kit comprising in a compartmentalized container (1) an antibody selectively immunoreactive with 5-FU, and (2) a DPD inactivator.
A transferring syringe assembly, comprising:
- a barrel defining a chamber of the transferring syringe and having a tip extending from a distal end of said barrel;
- a plunger slidably inserted inside the chamber of said barrel;
- a tip shield attached to the tip or extending from the distal end of said barrel longitudely along said tip;
- and
- a tip cap operably connected to said tip or tip shield, interlocking with said tip shield thereby sealing said tip.
A transferring syringe assembly, comprising:
- a barrel defining a chamber of the transferring syringe and having a tip extending from a distal end of said barrel;
- a plunger slidably inserted inside the chamber of said barrel;
- and
- a needle cover having a needle operably connected to said tip, wherein said needle cover has a generally tubular body coaxially disposed about the needle, and a tubular wall extending along the needle and beyond the sharpened tip of the needle.
Dependencies are inferred from the claim text.